Search

Your search keyword '"Buck, Andreas K."' showing total 748 results
Start Over Author "Buck, Andreas K." Publication Type Academic Journals
748 results on '"Buck, Andreas K."'

1. Cranioencephalic functional lymphoid units in glioblastoma

Author

Dobersalske, Celia, Rauschenbach, Laurèl, Hua, Yichao, Berliner, Christoph, Steinbach, Anita, Grüneboom, Anika, Kokkaliaris, Konstantinos D., Heiland, Dieter H., Berger, Pia, Langer, Sarah, Tan, Chin L., Stenzel, Martin, Landolsi, Somaya, Weber, Flora, Darkwah Oppong, Marvin, Werner, Rudolf A., Gull, Hanah, Schröder, Thomas, Linsenmann, Thomas, Buck, Andreas K., Gunzer, Matthias, Stuschke, Martin, Keyvani, Kathy, Forsting, Michael, Glas, Martin, Kipnis, Jonathan, Steindler, Dennis A., Reinhardt, Hans Christian, Green, Edward W., Platten, Michael, Tasdogan, Alpaslan, Herrmann, Ken, Rambow, Florian, Cima, Igor, Sure, Ulrich, and Scheffler, Björn

Published
2024
Full Text
View/download PDF

44. DNA Damage and Repair in PBMCs after Internal Ex Vivo Irradiation with [ 223 Ra]RaCl 2 and [ 177 Lu]LuCl 3 Mixtures.

Author

Strobel, Isabella, Schumann, Sarah, Müller, Jessica, Buck, Andreas K., Port, Matthias, Lassmann, Michael, Eberlein, Uta, and Scherthan, Harry

Subjects
DNA repair, DOUBLE-strand DNA breaks, NUCLEAR power plant accidents, MONONUCLEAR leukocytes, NUCLEAR power plants
Abstract

The combination of high and low LET radionuclides has been tested in several patient studies to improve treatment response. Radionuclide mixtures can also be released in nuclear power plant accidents or nuclear bomb deployment. This study investigated the DNA damage response and DNA double-strand break (DSB) repair in peripheral blood mononuclear cells (PBMCs) after internal exposure of blood samples of 10 healthy volunteers to either no radiation (baseline) or different radionuclide mixtures of the α- and β-emitters [223Ra]RaCl2 and [177Lu]LuCl3, i.e., 25 mGy/75 mGy, 50 mGy/50 mGy and 75 mGy/25 mGy, respectively. DSB foci and γ-H2AX α-track enumeration directly after 1 h of exposure or after 4 h or 24 h of repair revealed that radiation-induced foci (RIF) and α-track induction in 100 cells was similar for mixed α/β and pure internal α- or β-irradiation, as were the repair rates for all radiation qualities. In contrast, the fraction of unrepaired RIF (Qβ) in PBMCs after mixed α/β-irradiation (50% 223Ra & 50% 177Lu: Qβ = 0.23 ± 0.10) was significantly elevated relative to pure β-irradiation (50 mGy: Qβ, pure = 0.06 ± 0.02), with a similar trend being noted for all mixtures. This α-dose-dependent increase in persistent foci likely relates to the formation of complex DNA damage that remains difficult to repair. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand

Author

Boschi, Stefano, Lee, Jason T, Beykan, Seval, Slavik, Roger, Wei, Liu, Spick, Claudio, Eberlein, Uta, Buck, Andreas K, Lodi, Filippo, Cicoria, Gianfranco, Czernin, Johannes, Lassmann, Michael, Fanti, Stefano, and Herrmann, Ken

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Biomedical Imaging, Cancer, Bioengineering, Animals, Antigens, Surface, Biomarkers, Tumor, Cell Line, Tumor, Drug Evaluation, Preclinical, Edetic Acid, Fluorine Radioisotopes, Gallium Isotopes, Gallium Radioisotopes, Glutamate Carboxypeptidase II, Isotope Labeling, Male, Metabolic Clearance Rate, Mice, Mice, Inbred C57BL, Oligopeptides, Organ Specificity, Organometallic Compounds, Positron-Emission Tomography, Prostatic Neoplasms, Radiation Dosage, Radiation Exposure, Radiopharmaceuticals, Reproducibility of Results, Sensitivity and Specificity, Tissue Distribution, Whole-Body Counting, PET, PSMA, F-18, Dosimetry, Preclinical, Prostate cancer, 18F, Other Physical Sciences, Nuclear Medicine & Medical Imaging, Clinical sciences
Abstract

PurposeThe aim of this study was to synthesize and preclinically evaluate an 18F-PSMA positron emission tomography (PET) tracer. Prostate-specific membrane antigen (PSMA) specificity, biodistribution, and dosimetry in healthy and tumor-bearing mice were determined.MethodsSeveral conditions for the labeling of 18F-PSMA-11 via 18F-AlF-complexation were screened to study the influence of reaction temperature, peptide amount, ethanol volume, and reaction time. After synthesis optimization, biodistribution and dosimetry studies were performed in C57BL6 mice. For proof of PSMA-specificity, mice were implanted with PSMA-negative (PC3) and PSMA-positive (LNCaP) tumors in contralateral flanks. Static and dynamic microPET/computed tomography (CT) imaging was performed.ResultsQuantitative labeling yields could be achieved with >97 % radiochemical purity. The 18F-PSMA-11 uptake was more than 24-fold higher in PSMA-high LNCaP than in PSMA-low PC3 tumors (18.4 ± 3.3 %ID/g and 0.795 ± 0.260 %ID/g, respectively; p

Published
2016

50. 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT

Author

Bluemel, Christina, Krebs, Markus, Polat, Bülent, Linke, Fränze, Eiber, Matthias, Samnick, Samuel, Lapa, Constantin, Lassmann, Michael, Riedmiller, Hubertus, Czernin, Johannes, Rubello, Domenico, Bley, Thorsten, Kropf, Saskia, Wester, Hans-Juergen, Buck, Andreas K, and Herrmann, Ken

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Bioengineering, Prostate Cancer, Clinical Research, Urologic Diseases, Biomedical Imaging, Cancer, Aged, Aged, 80 and over, Antigens, Surface, Choline, Gallium Radioisotopes, Glutamate Carboxypeptidase II, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, choline-PET/CT, PSMA-PET/CT, prostate cancer, recurrence, restaging, Nuclear Medicine & Medical Imaging, Clinical sciences
Abstract

PurposeInvestigating the value of Ga-PSMA-PET/CT in biochemically recurring prostate cancer patients with negative F-choline-PET/CT.Patients and methodsOne hundred thirty-nine consecutive patients with biochemical recurrence after curative (surgery and/or radiotherapy) therapy were offered participation in this sequential clinical imaging approach. Patients first underwent an F-choline-PET/CT. If negative, an additional Ga-PSMA-PET/CT was offered. One hundred twenty-five of 139 eligible patients were included in the study; 32 patients underwent additional Ga-PSMA-PET/CT. Patients with equivocal findings (n = 5) on F-choline-PET/CT and those who declined the additional Ga-PSMA-PET/CT (n = 9) were excluded. Images were analyzed visually for the presence of suspicious lesions. Findings on PET/CT were correlated with PSA level, PSA doubling time (dt), and PSA velocity (vel).ResultsThe overall detection rates were 85.6% (107/125) for the sequential imaging approach and 74.4% (93/125) for F-choline-PET/CT alone. Ga-PSMA-PET/CT detected sites of recurrence in 43.8% (14/32) of the choline-negative patients. Detection rates of the sequential imaging approach and F-choline-PET/CT alone increased with higher serum PSA levels and PSA vel. Subgroup analysis of Ga-PSMA-PET/CT in F-choline negative patients revealed detection rates of 28.6%, 45.5%, and 71.4% for PSA levels of 0.2 or greater to less than 1 ng/mL, 1 to 2 ng/mL, and greater than 2 ng/mL, respectively.ConclusionsThe sequential imaging approach designed to limit Ga-PSMA imaging to patients with negative choline scans resulted in high detection rates. Ga-PSMA-PET/CT identified sites of recurrent disease in 43.8% of the patients with negative F-choline PET/CT scans.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results